Table 1.
Influence of atropine, eserine and HC-3 on plasma glucose levels in STZ rats that underwent EA treatment at ST-36.
| Group (n = 6) | Before | After | HGA% |
|---|---|---|---|
| Atropine + EA | 413 ± 29 | 408 ± 32 | –1 ± 4 |
| Atropine | 480 ± 51 | 480 ± 54 | 0 ± 2 |
| Eserine + EA | 406 ± 55 | 331 ± 57** | –19 ± 6# |
| Eserine | 460 ± 111 | 417 ± 105 | –9 ± 6 |
| HC-3 + EA | 510 ± 109 | 494 ± 106 | –3 ± 7 |
| HC-3 | 491 ± 61 | 471 ± 50 | –4 ± 4 |
The levels of plasma glucose are expressed as mean ± SEM (mg dl−1), n: sample number; atropine: atropine 0.1 mg kg−1 i.p. treatment; atropine + EA: atropine 0.1 mg kg−1 i.p. treatment prior to EA; eserine + EA: eserine 0.01 mg kg−1 i.p. treatment prior to EA; HC-3: HC-3, 5 μg kg−1 i.p. treatment; Before: plasma glucose levels 30 min following medicinal treatment; After: plasma glucose levels following 30 min of EA treatment to ST-36; HGA%: hypoglycemic activity; comparison of before and after EA treatment by self-pair t-test **P < .01 versus before; Student's t-test # P < .05 versus the control group.